reports
CASI Pharmaceuticals Inc: 1 director
A director at CASI Pharmaceuticals Inc bought 55,573 shares at 4.133USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Sean Conroy
CASI Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on Hepion Pharmaceuticals (HEPA), Hurricane Energy (HUR), CASI Pharmaceuticals (CASI) and Monarch Mining Corporation (GBAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
- Sean Conroy
CASI Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on Hepion Pharmaceuticals (HEPA), Hurricane Energy (HUR), CASI Pharmaceuticals (CASI) and Monarch Mining Corporation (GBAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
- Sean Conroy
CASI Pharmaceuticals - Evomela sales drive guidance upgrade
CASI’s Q221 results were driven by strong sales momentum in Evomela, its proprietary formulation of melphalan for multiple myeloma (MM) in China. The in-clinic pipeline continues to make steady progress, led by CNCT19 (CD19 targeting CAR-T therapy for B-ALL and B-NHL) nearing completion of pivotal Phase II studies. We have raised our FY21–23 revenue estimates, as well as peak sales potential for Evomela, acknowledging its rapid growth in the past few quarters and CASI’s guidance upgrade for 2021...
- Sean Conroy
CASI Pharmaceuticals - Evomela sales drive guidance upgrade
CASI’s Q221 results were driven by strong sales momentum in Evomela, its proprietary formulation of melphalan for multiple myeloma (MM) in China. The in-clinic pipeline continues to make steady progress, led by CNCT19 (CD19 targeting CAR-T therapy for B-ALL and B-NHL) nearing completion of pivotal Phase II studies. We have raised our FY21–23 revenue estimates, as well as peak sales potential for Evomela, acknowledging its rapid growth in the past few quarters and CASI’s guidance upgrade for 2021...
- Sean Conroy
CASI Pharmaceuticals - Continuing to execute
CASI continues to execute on multiple fronts and demonstrates that it has become a multifaceted company. It is expanding the sales of Evomela, its proprietary formulation of melphalan for multiple myeloma in China. Simultaneously, it is adding to its pipeline with new licensing deals and is executing on its development strategy, with four drug candidates currently in the clinic.
- Jonathan Moreland
GORO GOLD RESOURCE
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
CASI CASI PHARMACEUTICALS
ATSG AIR TRANSPORT SERVICES GROUP INC.
ADVM ADVERUM BIOTECHNOLOGIES
OPRX OPTIMIZERX CORP
GRBK GREEN BRICK PARTNERS
RSG REPUBLIC SERVICES INC.
VRTV VERITIV CORP
ATLC ATLANTICUS HOLDINGS CORP
TSI TCW STRATEGIC INCOME FUND INC.
HFBL HOME FEDERAL BANCORP INC. OF LOUISIANA
CNBKA CENTURY BANCORP INC. CL A
OSG OVERSEAS SHIPHOLDING GROUP
JRO NUVEEN FLOATING RATE INCOME OPPORTUNITY FUND
NOVN NOVAN INC
ASPU ASPEN GROUP INC
REVG REV GROUP INC.
FPH FIVE POINT HOLDINGS LLC CLASS A
MTEM MOLECULAR TEMPLATES
RCKT ROCKET PHARMACEUTICALS
CTIC CELL THERAPEUTICS
SLDB INC.
PRPL SOLID BIOSCIENCES INC
WINT PURPLE INNOVATION
CRNX INC.
BANX WINDTREE THERAPEUTICS INC
VRCA CRINETICS PHARMACEUTICALS
ANIX STONECASTLE FINANCIAL CORP
HHC VERRICA PHARMACEUTICALS
DBI ANIXA BIOSCIENCES
KFS THE HOWARD HUGHES CORPORATION
OSW DESIGNER BRANDS INC. CLASS A
LMPX KINGSWAY FINANCIAL SERVICES
DCTH ONESPAWORLD HOLDINGS (A)
NMTR LMP AUTOMOTIVE HOLDINGS
ADV INC.
HPK DELCATH SYSTEMS
AIV 9 METERS BIOPHARMA
BSTZ INC.
TPGY ADVANTAGE SOLUTIONS INC (A)
EDSA HIGHPEAK ENERGY INC (A)
DMS APARTMENT INVESTMENT & MANAGEMENT CO CLASS A
FTCV BLACKROCK SCIENCE AND TECHNOLOGY TRUST II
CYTH TPG PACE BENEFICIAL FINANCE
QS EDESA BIOTECH
EMPR DIGITAL MEDIA SOLUTIONS INC (A)
FGNA FINTECH ACQUISITION CORP V
CTOS CYCLO THERAPEUTICS
QUANTUMSCAPE
EMPRESS ROYALTY
FG NEW AMERICA ACQUISITION
CUSTOM TRUCK ONE SOURCE
INC.
CASI Pharmaceuticals - Continuing to advance and expand the pipeline
The year 2020 was one of challenges for CASI, as it was for the rest of the world, but the company was able to continue to advance the commercialization of Evomela and jumpstart its clinical development engine. CASI is continuing to execute on its strategy of opportunistically in-licensing assets and the recent trend has been to earlier-stage assets such as its latest acquisition, the Chinese rights to the Phase I broad spectrum anti-cancer drug CB-5339, announced in March.
- Jonathan Moreland
- Sean Conroy
CASI Pharmaceuticals - Evomela sales going strong into 2021
CASI has announced as part of its preliminary results that it sold $4.8m worth of Evomela in Q420 and approximately $15m for the year (unaudited), exceeding the company guidance of $14m and our estimate of $14.4m. The company stated that it is targeting 50% growth in Evomela sales in 2021. Additionally, in 2021 the company will be jump starting its clinical development engine as it is expected to initiate clinical studies on a majority of its portfolio during the year.
- Jonathan Moreland
TESS TESSCO TECHNOLOGIES INC.
PRTY PARTY CITY HOLDCO INC.
MYE MYERS INDUSTRIES INC.
MACK MERRIMACK PHARMACEUTICALS INC
FFIC FLUSHING FINANCIAL CORP.
COTY COTY INC. CLASS A
CASI CASI PHARMACEUTICALS
SAFT SAFETY INSURANCE GROUP INC.
CERC CERECOR INC
FTK FLOTEK INDUSTRIES INC.
SPOK SPOK HOLDINGS
FLXS FLEXSTEEL INDUSTRIES INC.
GBDC GOLUB CAPITAL BDC INC.
QRTEA QURATE RETAIL INC. CLASS A
BASA BASF SE ADS
ISNS IMAGE SENSING SYSTEMS INC.
LAZY LAZYDAYS HOLDINGS
WSTG WAYSIDE TECHNOLOGY
GTXMQ GARRETT MOTION INC.
KOD KODIAK SCIENCES
VTA INVESCO DYNAMIC CREDIT OPPORTU
UONEK URBAN ONE INC CLASS D
BW BABCOCK & WILCOX ENTERPRISES
FSLF THL CREDIT SENIOR LOAN FUND
FTSI FTS INTERNATIONAL INC. CLASS A
EMYB EMBASSY BANCORP INC.
- Jonathan Moreland
FFIC FLUSHING FINANCIAL CORP.
EIG EMPLOYERS HOLDINGS INC.
COTY COTY INC. CLASS A
CASI CASI PHARMACEUTICALS
SPOK SPOK HOLDINGS
GBDC GOLUB CAPITAL BDC INC.
QRTEA QURATE RETAIL INC. CLASS A
LAZY LAZYDAYS HOLDINGS
KOD KODIAK SCIENCES
FTSI FTS INTERNATIONAL INC. CLASS A
- Sean Conroy
CASI Pharmaceuticals - Pivotal CAR-T study initiated
CASI announced on 19 November 2020 that its partner Juventas has initiated pivotal studies of the CD19 CAR-T product CNCT19 for the treatment of B-cell non-Hodgkin lymphoma (B-NHL). The clinical study will be run by Juventas at its expense, which will be supported by its recent $65m financing round, and the two companies will subsequently co-market in China if the product is approved. Juventas has guided towards potential approval in Q422.
- Sean Conroy
CASI Pharmaceuticals - New drug licensed targeting antibody checkpoint...
CASI announced that it has in licensed the Greater Chinese rights to BI-1206 from BioInvent, which is being investigated in Phase I trials for the treatment of non-Hodgkin lymphoma (NHL) and solid tumors. The drug has a novel target FcγRIIB, an antibody receptor on leukocytes with checkpoint-like properties. The drug is currently in two dose escalation studies for NHL and solid tumors in combination with rituximab and Keytruda, respectively.
- Sean Conroy
CASI Pharmaceuticals - CASI restructures CAR-T deal
CASI announced on 29 September 2020 that it had adjusted its licence and marketing agreement with Juventas, the developer of the CAR-T therapy CNCT19. Under the new agreement, the two companies will co-market the product and have a profit-sharing agreement, as opposed to the previous model in which CASI would have owed milestones and royalties (all undisclosed). The new agreement should make Juventas more viable as a standalone entity, capable of raising independent capital to support its intern...
- Sean Conroy
CASI Pharmaceuticals - Evomela supply secured, CNCT19 on track
CASI reported sales of $2.6m for Evomela in Q220, down slightly from Q1 ($3.4m). The lower revenue was due to logistics disruptions as the company shifted to a new supplier for the drug as well as impacts of COVID-19. Management indicates that the new suppler will substantially improve cost-of-goods. The company is guiding to sales of at least $10m for 2020, but believes that this is a conservative estimate.
- Jonathan Moreland
- Jonathan Moreland
BLMN BLOOMIN' BRANDS INC.
WCC WESCO INTERNATIONAL INC.
VSAT VIASAT INC.
SPPI SPECTRUM PHARMACEUTICALS INC.
SAR SARATOGA INVESTMENT CORP.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RHP RYMAN HOSPITALITY PROPERTIES INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PFG PRINCIPAL FINANCIAL GROUP INC.
MI7 MITCHAM INDUSTRIES
KIRK KIRKLAND'S INC.
HT HERSHA HOSPITALITY TRUST CLASS A
GTIM GOOD TIMES RESTAURANTS INC
GLP GLOBAL PARTNERS LP
ESCA ESCALADE INC.
CLR CONTINENTAL RESOURCES INC.
CASI CASI PHARMACEUTICALS
AZZ AZZ INC.
AXSM AXSOME THERAPEUTICS
ALDX ALDEYRA THERAPEUTICS
OPRX OPTIMIZERX CORP
ATLC ATLANTICUS HOLDINGS CORP
AGX ARGAN INC.
TRC TEJON RANCH CO.
GHC GRAHAM HOLDINGS CO.
EDF STONE HARBOR EMERGING MARKETS INCOME FUND
ZDGE ZEDGE
CNBKA CENTURY BANCORP INC. CL A
OSG OVERSEAS SHIPHOLDING GROUP
GNUS GENIUS BRANDS INTL INC
LPTX LEAP THERAPEUTICS
WTI W&T OFFSHORE
VST INC.
RESI VISTRA CORP.
USM FRONT YARD RESIDENTIAL CORP. CLASS B
IDRA UNITED STATES CELLULAR CORPORATION
CCEL IDERA PHARMACEUTICALS
MGTA CRYO-CELL INTERNATIONAL
PRSP MAGENTA THERAPEUTICS
NGM PERSPECTA
PBYI NGM BIOPHARMACEUTICALS
SSSS INNOVATIVE ACQUISITIONS CORP
ETNB SUTTER ROCK CAPITAL CORP
FRG 89BIO
EVF FRANCHISE GROUP
AXGT EATON VANCE SENIOR INCOME TRUST
PSTI SIO GENE THERAPIES INC
VOXX PLURISTEM THERAPEUTICS INC
TTI AUDIOVOX CORPORATION
HYSR ROPER BROTHERS INC
AWH HYPERSOLAR INC
SPE ASPIRA WOMEN'S HEALTH INC.
FLUX SPECIAL OPPORTUNITIES FUND
INC.
FLUX POWER HOLDINGS INC
- Jonathan Moreland
GEO GEO GROUP INC. (THE)
CARR CARRS GROUP
VGR VECTOR GROUP LTD.
SYY SYSCO CORPORATION
STOR STORE CAPITAL CORPORATION
STFC STATE AUTO FINANCIAL CORP.
SREV SERVICESOURCE INTERNATIONAL INC.
SCM STELLUS CAPITAL INVESTMENT CORP
SASR SANDY SPRING BANCORP INC.
SAR SARATOGA INVESTMENT CORP.
SANW S&W SEED CO
RM REGIONAL MANAGEMENT CORP
OCUL OCULAR THERAPEUTIX
NMFC NEW MOUNTAIN FINANCE CORPORATION
HSC HARSCO CORPORATION
A2AM8Y CARDTRONICS PLC CLASS A
CASI CASI PHARMACEUTICALS
MLVF MALVERN BANCORP
CBFV CB FINANCIAL SERVICES INC.
MDU MDU RESOURCES GROUP INC
MCY MERCURY NZ LTD.
ADC AGREE REALTY CORPORATION
CCRN CROSS COUNTRY HEALTHCARE INC.
WPC W. P. CAREY INC.
CNBKA CENTURY BANCORP INC. CL A
OSG OVERSEAS SHIPHOLDING GROUP
ARNC HOWMET AEROSPACE INC.
PHD PIONEER FLOATING RATE
CDEV CENTENNIAL RESOURCE DEVELOPMENT INC. CLASS A
CLPR CLIPPER REALTY
AES THE AES CORPORATION
MYOV MYOVANT SCIENCE
STKL SUNOPTA
ESQ INC.
WTBA ESQUIRE FINANCIAL HOLDINGS
GTES WEST BANCORP INC.
CBTX GATES INDUSTRIAL CORP
STXB CBTX
NHS SPIRIT OF TEXAS BANCSHARES
ETRN NEUBERGER BERMAN HIGH YIELD ST
CNR EQUITRANS MIDSTREAM CORP
SSSS CORNERSTONE BUILDING BRANDS INC
AXLA SUTTER ROCK CAPITAL CORP
CRTX AXCELLA HEALTH
CTVA CORTEXYME
HBT CORTEVA
ANDE INC.
EVF HBT FINANCIAL
NREF THE ANDERSONS
PROS INC.
RC EATON VANCE SENIOR INCOME TRUST
RPT NEXPOINT REAL ESTATE FINANCE
HGBL INC.
TPC PROSIGHT GLOBAL
BRKB GRUPO RADIO CENTRO S.A.B. DE C.V.
RAMCO GERSHENSON PROPERTIES TRUST
HERITAGE GLOBAL
TRITON PCS HOLDINGS INC
BERKSHIRE HATHAWAY INC.
- Jonathan Moreland
SREV SERVICESOURCE INTERNATIONAL INC.
SCM STELLUS CAPITAL INVESTMENT CORP
SANW S&W SEED CO
OXFD OXFORD IMMUNOTEC GLOBAL
OCUL OCULAR THERAPEUTIX
CASI CASI PHARMACEUTICALS
BOCH BANK OF COMMERCE HOLDINGS
MCY MERCURY NZ LTD.
CCRN CROSS COUNTRY HEALTHCARE INC.
WPC W. P. CAREY INC.
CNBKA CENTURY BANCORP INC. CL A
OSG OVERSEAS SHIPHOLDING GROUP
PHD PIONEER FLOATING RATE
CDEV CENTENNIAL RESOURCE DEVELOPMENT INC. CLASS A
CRVL CORVEL CORP.
MYOV MYOVANT SCIENCE
CLAR CLARUS CORPORATION
USX US XPRESS ENTERPRISES INC
NHS NEUBERGER BERMAN HIGH YIELD ST
MIDD THE MIDDLEBY CORPORATION
SSSS SUTTER ROCK CAPITAL CORP
AXLA AXCELLA HEALTH
EVF EATON VANCE SENIOR INCOME TRUST
NREF NEXPOINT REAL ESTATE FINANCE
RC INC.
TRMK GRUPO RADIO CENTRO S.A.B. DE C.V.
IFRB CORP
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.